AllSight
Companies · INCY · Services-Commercial Physical & Biological Research

INCYTE CORP (INCY)

INCYTE CORP (INCY) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

INCYTE CORP (INCY) stock — financials & valuation

Key numbers for INCYTE CORP (INCY): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 78/100 — a percentile rank of INCYTE CORP’s fundamentals against Services peers, weakest on valuation. A quality ranking, not a price prediction.

Market cap$24.6B
P / E15.3×
P / S4.2×
EV / EBITDA10.6×
Gross margin92.6%
Operating margin30.6%
Net margin27.7%
Return on equity25.4%
ROIC60.9%
Revenue growth26.9%
Debt / equity0.0×
Dividend yield0.0%

Is INCYTE CORP overvalued? P/E looks undervalued vs its 5-year range; P/S looks fair vs its 5-year range; EV/EBITDA looks undervalued vs its 5-year range; P/B looks fair vs its 5-year range.

Independent of the events above — derived from INCYTE CORP’s own financial statements and shown as context, never as advice.

Aug 31, 2026CMS pricing agreement
Incyte secures CMS pricing deal: Medicaid concession buys GUARD, GLOBE protection
Related companies in Services-Commercial Physical & Biological Research
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact